Aptargroup, Inc. (NYSE: ATR)

Sector: Healthcare Industry: Medical Instruments & Supplies CIK: 0000896622
Market Cap 8.18 Bn
P/B 2.95
P/E 19.50
P/S 2.23
ROIC (Qtr) 12.61
Div Yield % 1.48
Rev 1y % (Qtr) 5.70
Total Debt (Qtr) 703.79 Mn
Debt/Equity (Qtr) 0.25

About

AptarGroup, Inc., often referred to as Aptar, is a prominent player in the design and manufacturing of drug and consumer product dosing, dispensing, and protection technologies. The company operates across various end markets, including pharmaceutical, beauty, food, beverage, personal care, and home care. With a presence in 20 countries and approximately 13,800 dedicated employees, Aptar caters to a diverse range of customers, many of whom are leading brands globally. Aptar's primary offerings include dispensing pumps, closures, aerosol valves,...

Read more

Price action

Investment thesis

Bull case

  • Strong operating cash flow of 564.54M provides robust 0.80x coverage of total debt 703.79M, indicating excellent debt servicing capability and financial flexibility.
  • Operating cash flow of 564.54M provides exceptional 11.98x coverage of interest expenses 47.10M, showing strong debt service capability.
  • Operating cash flow of 564.54M provides strong 12.15x coverage of stock compensation 46.46M, indicating sustainable incentive practices.
  • Strong tangible asset base of 3.77B provides 5.36x coverage of total debt 703.79M, indicating robust asset backing and low credit risk.
  • Long-term investments of 130.35M provide solid 2.65x coverage of long-term debt 49.22M, indicating strategic financial planning.

Bear case

  • Operating cash flow of 564.54M barely covers its investment activities of (386.18M), with a coverage ratio of -1.46, indicating heavy reliance on external financing for growth which may not be sustainable in a tighter credit environment.
  • Operating cash flow of 564.54M provides thin coverage of dividend payments of (119.23M) with a -4.73 ratio, suggesting potential dividend sustainability issues if operational performance deteriorates.
  • Cash reserves of 257.06M provide limited coverage of acquisition spending of (28.22M), which is -9.11x, suggesting aggressive expansion might strain liquidity if market conditions deteriorate.
  • Operating earnings of 563.33M show weak coverage of depreciation charges of 278.24M, with a 2.02 ratio indicating high capital intensity and potential reinvestment needs.
  • High depreciation of 278.24M relative to operating cash flow of 564.54M, which is 0.49x suggests significant maintenance capital requirements affecting free cash flow.

Geographical Breakdown of Revenue (2024)

Segments Breakdown of Revenue (2024)

Peer comparison

Companies in the Medical Instruments & Supplies
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ISRG Intuitive Surgical Inc 209.14 Bn 76.14 21.76 0.00 Bn
2 BDX Becton Dickinson & Co 58.36 Bn 34.78 2.67 19.18 Bn
3 ALC Alcon Inc 39.57 Bn 37.80 3.89 5.24 Bn
4 RMD Resmed Inc 37.01 Bn 25.74 7.04 0.85 Bn
5 WST West Pharmaceutical Services Inc 19.95 Bn 40.58 6.61 0.30 Bn
6 HOLX Hologic Inc 16.94 Bn 29.95 4.13 2.52 Bn
7 COO Cooper Companies, Inc. 16.64 Bn 44.39 4.07 2.51 Bn
8 SOLV Solventum Corp 15.00 Bn 9.84 1.79 5.14 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 1.69 3.14
EV to Cash from Ops. EV/CFO 15.27 37.60
EV to Debt EV to Debt 12.25 23.10
EV to EBIT EV/EBIT 15.30 50.25
EV to EBITDA EV/EBITDA 10.87 19.58
EV to Free Cash Flow [EV/FCF] EV/FCF 27.15 -19.40
EV to Market Cap EV to Market Cap 1.05 -1.68
EV to Revenue EV/Rev 2.35 171.31
Price to Book Value [P/B] P/B 2.95 6.03
Price to Earnings [P/E] P/E 19.50 204.20
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Div Coverage (Qtr) 3.52 -1.11
Dividend Payout Ratio % Div Payout % (Qtr) 28.30 1.52
Dividend per Basic Share Div per Share (Qtr) 1.35 0.25
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 27.94 8.75
Interest Coverage Int. cover (Qtr) 11.96 -119.10
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex 1y % (Qtr) 15.16 -55.01
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) -21.03 200.65
Dividend Growth (1y) % Div 1y % (Qtr) -21.51 -1.49
EBIAT Growth (1y) % EBIAT 1y % (Qtr) 23.95 -56.39
EBITDA Growth (1y) % EBITDA 1y % (Qtr) 9.95 -106.80
EBIT Growth (1y) % EBIT 1y % (Qtr) 17.91 -36.51
EBT Growth (1y) % EBT 1y % (Qtr) 18.75 -47.44
EPS Growth (1y) % EPS 1y % (Qtr) 25.00 -15.70
FCF Growth (1y) % FCF 1y % (Qtr) -19.34 59.41
Gross Profit Growth (1y) % Gross Profit 1y % (Qtr) 4.30 68.22
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.72 0.54
Cash Payout Ratio Cash Payout (Qtr) 0.15 0.03
Cash Ratio Cash Ratio (Qtr) 0.17 2.49
Current Ratio Curr Ratio (Qtr) 1.19 7.77
Debt to Equity Ratio Debt/Equity (Qtr) 0.25 0.55
Interest Cover Ratio Int Coverage (Qtr) 11.96 -119.10
Times Interest Earned Times Interest Earned (Qtr) 11.96 -119.10
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % (Qtr) 23.00 -2,368.64
EBIT Margin % EBIT Margin % (Qtr) 15.38 -2,472.65
EBT Margin % EBT Margin % (Qtr) 14.09 -2,442.59
Gross Margin % Gross Margin % (Qtr) 38.10 30.07
Net Profit Margin % Net Margin % (Qtr) 11.50 -2,438.52